About Us

Rich Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development of its lead product, RP-323, (12-O- tetradecanoyl- phorbol-13-acetate), for the treatment of acute myelogenous leukemia (AML) in refractory patients. The basis for the interest of the Company to pursue clinical development of TPA in these and possibly other indications is the result of the Prof. Richard Chang.  He has conducted research on TPA for many years and have become an expert in the characteristics of this molecule. Their findings form the scientific basis for the clinical use of TPA. » Read more about us

Latest News

March 21

Rich Pharmaceuticals To Launch CannCodex, marking its entry into Medicinal Cannabis Industry View Release

February 28

Rich Pharmaceuticals Attracts New Financing Package with GHS Investments, LLC View Release

September 27

Rich Pharmaceuticals, Inc. Announces Quarterly Milestones View Release

» Read Latest News